Top Tech Companies (39)
Don't see your company?
Create a company profile
Esco Lifesciences is a world-leading manufacturer and service provider of life science tools. Esco contributes to meeting the challenges of the 21st century with a diverse range of business units—Scientific, Medical, Healthcare, and Aster. The company continuously innovates its products to help clinical and industrial laboratories conduct successful research and development, quality control, and analysis. Esco continues to provide reliable world-class equipment to help pharmaceutical companies make safer and more cost-effective products. And with the increasing demand of the IVF industry, the company has developed efficient ART equipment to enable equitable access to infertility care. With its global headquarters in Singapore, Esco has an extensive sales network that spans more than 100 countries, direct sales and service offices in over 21 countries, 8 manufacturing and R&D centers in the US, Europe, the UK, China, and Singapore, and more than 1500 employees globally.
ProfilePrint is an A.I.-driven predictive and prescriptive profiler, providing users with accessible, affordable, and portable solutions to ascertain and predict quality and profile of a food ingredient at the point of use, within seconds. Today, an enormous amount of resources are required to physically grade food samples across multiple stages of the global supply chain. ProfilePrint’s solution redefines transaction standards, and offers sellers and buyers an unbiased reference point, expediting existing quality assessment processes – from the farm all the way to end-buyers. Our headquarter is in Singapore with sales offices in Belgium, Japan and China. Founded in 2017, ProfilePrint is funded by international venture funds, Singapore government and strategic investors including Cargill, Louis Dreyfus, Olam, Sucafina and Sinar Mas. Our solution is deployed in over 26 cities globally across five continents (North America, Latin America, Africa, Europe and Asia).
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of disease, it’s no wonder that what we do each day is more than just a job. There’s an energy across IDEXX that is contagious – where caring and committed people come together to make things better. IDEXX Laboratories, Inc. (NASDAQ: IDXX), a member of the S&P 500, is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. Headquartered in southern Maine, we conduct operations through more than 70 locations around the world and serve customers in over 175 countries. Our primary business focuses on pet health, a growing market around the world. Our products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. We also develop and manufacture diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water and milk. Please visit our website, IDEXX.com/careers, for further information and to view all of our job opportunities.
Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
AMILI is a precision gut microbiome company based in Singapore, serving the region. Through AMILI's proprietary analytics engine, PRIME, we develop diagnostics tests, predictive algorithms and microbiome-modifying interventions. Our consumer health arm, BIO & ME, utilises insights from AMILI's database and PRIME to generate Asia-centric solutions towards personalised diet, supplementation and precision health. AMILI also houses Southeast Asia's first and only gut microbiome bank for clinical use and research. For more information, visit www.amili.asia.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
Livestock disease prevention and sustainable agri productivity. Singaporean synbio startup funded by EF Venture Capital.
AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element. Mice, test tubes, and other conventional preclinical models don't truly represent the complexities of the human body. Ninety percent of potential new drugs fail in humans because of the limited insight and misleading data generated in most preclinical drug studies. AIM's plug-and-play 3D cell culture systems change all of that: by enabling the equipment you already use in your lab to mimic the human microenvironment, your research project can get more predictive data at every stage. Make more informed decisions, save time, save resources. And to help you manage it, we also offer contract research services with the prestigious Institute of Molecular and Cell Biology—so you can benefit from our unique, human-focused approach to research in a world-class laboratory.
We are a bunch of highly experienced doctors, technologists, insurance experts and managed care practitioners who believe that we can use technology to improve the quality of Asian healthcare while lowering costs. We also know what works in Asia, and we brought best-in-class technologies from around the world on to one platform to make that belief a reality. We get paid on outcomes, plain and simple.
Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey. MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics. Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases. We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.
Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers in Singapore, China and Brazil. We are continuously expanding our global footprint through cooperative R&D, investment, mergers and acquisitions. Focusing on oncology and chronic diseases, Virtue Diagnostics utilizes innovative technology platforms such as clinical mass spectrometry, multiplex immunohistochemistry and molecular diagnostics to expand the China market. Through local capabilities built in emerging countries, Virtue is providing completed diagnostics menu cross biochemistry, chemiluminescence and molecular technologies.
Entobel is converting low value organic substrate into high quality products thanks to insects. Our main current products are sustainable animal feed (proteins and oils) and organic fertilizer. Since 2013, Entobel is running a commercial scale production site in Vietnam and exporting products worldwide. Entobel complies with highest standards in the industry (ISO 22000), only use tracable feedstocks and is FDA approved. Entobel is looking for strong partners to join for its expansion plans. Don't hesitate to contact us for more information.
